Biotech | March 06, 2022
Aquestive Therapeutics and Haisco Pharmaceutical partner for riluzole in China.
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
The CO2 Optimization module is one of the four modules (Product Costing, BoM Management, CO2 Optimization, Supplier Strategy) within the entire NDC Simulation Suite
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Brinton Pharmaceuticals enters exclusive sales and distribution rights of Scholl foot care products including Krack cream
Company expects strong organic growth in sales, EBITDA in 2022
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
Subscribe To Our Newsletter & Stay Updated
